[1] 曾民德. 非酒精性脂肪性肝病:回顾历史,展望未来. 实用肝脏病杂志, 2016, 19:129-131.
[2] Lee J H, Su J J. What is the appropriate strategy for diagnosing NAFLD using ultrasonography in obese children? World J Pediatr, 2017, 13:1-7.
[3] Félix DR, Costenaro F, Coral GP. Non-alcoholic fatty liver disease (Nafld) in obese children- effect of refined carbohydrates in diet. BMC Pediatr, 2016, 16:187-189.
[4] Pampanini V, Inzaghi E, Germani D, et al. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 2018, 28:71-76.
[5] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志, 2010, 49:275-278.
[6] Snf A, Ncb S, Alves C D, et al. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update. Nutr Hosp, 2017, 34:727-730.
[7] Shi J Q, Shen W X, Wang X Z, et al. Relationship Between immune parameters and non-alcoholic fatty liver disease in obese children. Indian Pediatr, 2017, 54:825-829.
[8] Villela-Nogueira C A, Leite N C, Cardoso C R L, et al. NAFLD and increased aortic stiffness: parallel or common physiopatho-logical mechanisms? Int J Mol Sci, 2016, 17:460-465.
[9] Effendi K, Harada K, Hashimoto E, et al. Pathological findings of NASH and NAFLD: for guidebook of NASH and NAFLD. Hepatol Res, 2017, 47:3-10.
[10] Pacifico L, Andreoli G M, D′Avanzo M, et al. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease. World J Gastroenterol, 2018, 24:2073-2082. |
